Adaptive Biotechnologies Co. (NASDAQ: ADPT) had its price target raised by analysts at Piper Sandler from $6.00 to $7.00. They now have an "overweight" rating on the stock.
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
Earnings To Watch: Adaptive Biotechnologies Corp (ADPT) Reports Q3 2024 Result [Yahoo! Finance]